The most interesting and impactful trial presented at the AHA this week (and simultaneously published in the New England Journal of Medicine) was the SAMSON trial,…
New ORBITA Findings May Offer Modest Symptomatic Pain Relief To Interventional Cardiologists
New data presented at EuroPCR from the much debated ORBITA trial may provide some modest temporary lessening of the pain felt by interventional cardiologists in…
Cardiology World Erupts Into Controversy Over Change In Major Clinical Trial
As a major clinical trial in cardiology nears completion it has provoked a storm of criticism and controversy. The brouhaha erupted in response to a…
More Mini-Trials And Fewer Mega-Trials?
Just as dinosaurs ruled the earth for millions of years, for more than 30 years now cardiology has been ruled by mega-trials. Over the years…
Will ORBITA Change Clinical Practice? The Role of Perverse Economic Incentives
Editor’s note: In this guest post Sanjay Kaul (Cedars-Sinai) explains why it is unlikely that the ORBITA trial will have a big impact on clinical…
In Defense Of ORBITA
–The trial investigators respond to their numerous critics. If you’ve been reading about ORBITA then you probably know that the first ever placebo-controlled trial of…
Why was ORBITA MIA at the AHA?
By offering a last minute 2-for-1 deal shortly before its annual meeting in Anaheim the American Heart Association signalled its desperation. During the meeting, as…
ORBITA Trial Puts Interventional Cardiologists On The Defensive
(Updated) Since it’s debut a week ago the ORBITA trial has provoked the most furious debate in cardiology since the COURAGE trial a decade earlier.…
The Story Behind The NY Times ORBITA Anecdote
–Brahmajee Nallamothu fills in the details about the patient who didn’t get a stent because of ORBITA. Editor’s note: The New York Times story by…
Diving Deep Into The ORBITA Trial
William Boden, Ajay Kirtane, and Dan Mark analyze the ORBITA trial. Editor’s note: I asked a wide variety of cardiologists for their thoughts about ORBITA,…